Skip to main content
    P

    Praxis Precision Medicines Inc (PRAX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $310.27
    -17.86 (-5.44%)

    Market Cap: $9.17B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Praxis Precision Medicines Inc (PRAX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Praxis Precision Medicines reported revenue of $0 for the fiscal year ended Dec 31, 2025, down 100.0% from the year before. That year, net income was -$303.27M, operating cash flow was -$249.07M and free cash flow was -$249.12M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$94.23M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $326.20M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0-100.0%N/AN/AN/A
    Dec 2024$8.55M+249.5%100.0%-2340.3%-2137.5%
    Dec 2023$2.45MN/A100.0%-5164.4%-5037.9%
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$0$8.55M$2.45M$0$0$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$1.00K
    Gross profit$0$8.55M$2.45M$0$0$0$0-$1.00K
    Research and development$267.12M$152.41M$86.77M$155.04M$120.26M$44.98M$29.56M$18.82M
    Operating income-$326.20M-$200.16M-$126.37M-$214.99M-$167.33M-$61.97M-$35.79M-$22.72M
    Net income-$303.27M-$182.82M-$123.28M-$214.03M-$167.06M-$61.82M-$35.51M-$26.54M
    EBITDA-$306.72M-$187.47M-$122.80M-$212.61M-$165.06M-$61.78M-$35.75MN/A
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$7.46M$302.00K$357.00K$431.00K$515.00K
    Gross profit$0$0$0-$28.00K$0$0$0$7.46M$302.00K$357.00K$431.00K$515.00K
    Operating income-$106.91M-$96.90M-$105.86M-$97.04M-$78.36M-$76.07M-$74.73M-$63.96M-$56.84M-$37.49M-$41.89M-$27.81M
    Net income-$94.23M-$83.72M-$92.56M-$88.91M-$73.93M-$71.13M-$69.30M-$58.68M-$51.91M-$32.68M-$39.55M-$26.88M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $110.00K by $357.22M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$937.91M$483.11M$87.95M$115.13M$292.75M$303.18M$47.69M$19.83M
    Current assets$610.91M$404.37M$84.88M$110.84M$287.41M$302.33M$45.50M$19.13M
    Cash and equivalents$357.33M$215.37M$81.30M$61.62M$138.70M$296.61M$44.81M$17.95M
    Total liabilities$59.77M$37.66M$18.28M$39.02M$41.94M$15.72M$7.58M$5.15M
    Short-term debt$110.00K$1.26M$1.13M$1.00M$4.31M$763.00K$696.00KN/A
    Shareholder equity$878.14M$445.45M$69.67M$76.11M$250.81M$287.46M-$81.01M$14.68M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.31B$1.39B$1.46B$937.91M$396.39M$452.83M$478.74M$483.11M$416.26M$441.06M$250.41M$87.95M
    Total liabilities$52.50M$49.06M$50.24M$59.77M$52.88M$48.61M$39.52M$37.66M$33.59M$21.96M$20.73M$18.28M
    Cash and equivalents$361.85M$474.76M$536.33M$357.33M$149.53M$157.41M$165.57M$215.37M$168.65M$145.14M$151.98M$81.30M
    Shareholder equity$1.26B$1.34B$1.41B$878.14M$343.50M$404.22M$439.21M$445.45M$382.67M$419.10M$229.68M$69.67M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$249.07M-$131.76M-$111.14M-$185.04M-$124.55M-$52.62M-$33.42M-$20.72M
    Capital expenditures$56.00K$0$50.00K$444.00K$1.05M$0$103.00K$63.00K
    Free cash flow-$249.12M-$131.76M-$111.19M-$185.49M-$125.60M-$52.62M-$33.52M-$20.78M
    Dividends paidN/AN/AN/A$811.00KN/A$696.00KN/AN/A
    Share repurchasesN/AN/AN/A$262.00K$575.00KN/AN/AN/A
    Investing cash flow-$311.15M-$248.49M$38.95M$96.89M-$140.52M$0-$103.00K-$63.00K
    Financing cash flow$702.17M$514.32M$91.87M$10.46M$107.59M$304.42M$60.39M$37.80M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$81.74M-$77.54M-$86.15M-$76.33M-$65.06M-$54.68M-$53.01M-$56.12M-$27.50M-$27.28M-$20.86M-$23.86M
    Capital expenditures$779.00K$1.02M$62.00K$0$0$56.00K$0$0$0$0$0$50.00K
    Free cash flow-$82.52M-$78.56M-$86.21M-$76.33M-$65.06M-$54.73M-$53.01M-$56.12M-$27.50M-$27.28M-$20.86M-$23.91M
    Last 12 quarters

    Frequently Asked Questions About PRAX

    What is Praxis Precision Medicines' annual revenue?

    Praxis Precision Medicines reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    How fast is Praxis Precision Medicines' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Praxis Precision Medicines profitable?

    No. Praxis Precision Medicines reported net income of -$303.27M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does PRAX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$249.07M minus capital expenditures of $56.00K produced free cash flow of -$249.12M.

    How much debt does Praxis Precision Medicines have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $110.00K and cash and equivalents of $357.33M.